Alnylam

Home » Alnylam

Secondary

Alnylam

They are a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating the expression of specific genes. ($675 million cash raise)

Symbol

ALNY

Last Closing Price
$129.11

Shares
4,000,000

Effective Date
November 14, 2017

Underwriters
Goldman Sachs, J.P. Morgan, Barclays

To view the prospectus for Alnylam, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253